CLINICAL TRIALS PROFILE FOR IMPLANON
✉ Email this page to a colleague
All Clinical Trials for IMPLANON
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00620464 ↗ | A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2005-05-01 | The primary purpose of this study is to demonstrate the bioequivalence of IMPLANON and Radiopaque IMPLANON. |
| NCT00725413 ↗ | A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2001-11-01 | The primary purpose of this study is to investigate the contraceptive efficacy, safety and acceptability of Organon's subdermal etonogestrel implant in healthy female volunteers in various countries in order to obtain country-specific data. |
| NCT00828542 ↗ | Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women | Completed | University of Sao Paulo | N/A | 2007-07-01 | The purpose of this study to assess the safety of the etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate puerperium of healthy women. |
| NCT00847587 ↗ | Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant | Completed | University of Utah | Phase 4 | 2009-01-01 | A highly effective single rod contraceptive implant is now available for use in the US. Delays in the insertion of the device until later in the postpartum period may negatively impact initiation rates. The objective of this study is to compare outcomes of early postpartum insertion (prior to postpartum hospital discharge) of the etonogestrel-releasing contraceptive implant with routine postpartum insertion at 4-8 weeks after delivery. Primary outcome of interest will be time to lactogenesis. Secondary outcomes will include rates of breastfeeding supplementation, infant growth, vaginal bleeding patterns, incidence of side effects, time to resume sexual intercourse after delivery, and incidence of missed routine postpartum follow-up. In addition, a subset of patients who randomize to early postpartum insertion will have expressed breastmilk ascertained for nutrient composition. |
| NCT00931827 ↗ | Acceptability of Long-term Progestin-only Contraception in Europe | Completed | Bayer | 2008-01-01 | The study examines the use of Mirena or Implanon for long-term contraception in women. The duration of therapy use is the key focus of the study. Also, any reasons for discontinuation and the safety profile will be examined. In addition, patients are asked to fill out a short questionnaire about their menstrual bleeding before and during therapy. | |
| NCT01356927 ↗ | Same-day Long-acting Reversible Contraception for Medication Abortion | Completed | Family Planning Fellowship | 2011-05-01 | Contraception after abortion is an important public health issue, as women who have an abortion are at high risk for additional unintended pregnancy. In the context of first trimester medical abortion, the standard of care is to administer long-acting reversible contraception, including the etonogestrel implant (Implanon) and depot medroxyprogesterone acetate (DMPA), at a follow-up appointment after the abortion. The investigators plan to conduct a prospective observational pilot study to evaluate the satisfaction of subjects who have selected either the contraceptive implant or DMPA given on the first day of medical abortion, as opposed to at a follow-up appointment. The investigators will also assess the continuation of DMPA and Implanon at 3, 6, 9, and 12 months after the initial date of administration. In addition, the investigators will assess the total days of bleeding after the abortion, follow-up rate for evaluation of completion of medical abortion, and efficacy of medical abortion. A total of 40 participants will be recruited, 20 who choose Implanon and 20 who choose DMPA. They will be asked to fill out questionnaires during the course of the study, and will be followed for one year. The study duration including data analysis will be two years. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IMPLANON
Condition Name
Clinical Trial Locations for IMPLANON
Trials by Country
Clinical Trial Progress for IMPLANON
Clinical Trial Phase
Clinical Trial Sponsors for IMPLANON
Sponsor Name
